Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO , May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
SOLANA BEACH, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company’s board of directors.
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ® New notice of allowance from USPTO to expand Gimoti patent estate SOLANA BEACH, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
SOLANA BEACH, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its first quarter 2021 financial results on
New patent expands intellectual property protection for nasal delivery of metoclopramide SOLANA BEACH, Calif. , April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the
SOLANA BEACH, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will
Encouraging early traction from GIMOTI™ commercial launch SOLANA BEACH, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
SOLANA BEACH, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2020
SOLANA BEACH, Calif. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock,
SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common
